

Annex I

Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)

Scientific conclusions

Taking into account the PRAC Assessment Report on the PSUR(s) for bisoprolol / perindopril, the scientific conclusions are as follows:

In view of available data on the risk of severe hypoglycaemia with concomitant use of beta-blockers with sulfonylureas from the literature and in view of a plausible mechanism of action, the PRAC considers a causal relationship between the concomitant use of bisoprolol /perindopril and sulfonylureas, and the increased risk of severe hypoglycaemia is at least a reasonable possibility. The PRAC concluded that the product information of products containing bisoprolol / perindopril should be amended accordingly.

Having reviewed the PRAC recommendation, the CMDh agrees with the PRAC overall conclusions and grounds for recommendation.

Grounds for the variation to the terms of the marketing authorisation(s)

On the basis of the scientific conclusions for bisoprolol / perindopril the CMDh is of the opinion that the benefit-risk balance of the medicinal product(s) containing bisoprolol / perindopril is unchanged subject to the proposed changes to the product information.

The CMDh recommends that the terms of the marketing authorisation(s) should be varied.

Annex II

Amendments to the product information of the nationally authorised medicinal product(s)

Amendments to be included in the relevant sections of the Product Information (new text underlined and in bold, deleted text ~~strike through~~)

Summary of Product Characteristics

- Section 4.4

The existing warning should be amended as follows:

Diabetic patients

Caution is advised when <Invented Name> is used in patients with diabetes mellitus with large fluctuations in blood glucose values. Symptoms of hypoglycaemia can be masked by beta-blockers.

Beta-blockers could further increase the risk of severe hypoglycaemia when used concurrently with sulfonylureas. Diabetic patients should be advised to carefully monitor blood glucose levels (see Section 4.5).

- Section 4.5

The existing information on the interaction with other medicinal products and other forms of interaction should be amended as follows:

Concomitant use which requires special care

Linked to bisoprolol and perindopril

Antidiabetic agents (insulins, oral hypoglycaemic agents)

[...]

Concomitant administration of bisoprolol with insulin and oral antidiabetic drugs may increase blood sugar lowering effect. Blockade of beta-adrenoreceptors may mask symptoms of hypoglycaemia. **The concomitant use of beta-blockers with sulfonylureas could increase the risk of severe hypoglycaemia (see Section 4.4).**

Package Leaflet

- Section 2

The existing information should be amended as follows:

Other medicines and <Invented name>

[...]

Make sure to tell your doctor if you are taking any of the following medicines:

[...]

- medication for diabetes including insulin and sulfonylureas (e.g. glibenclamide, **gliquidone, gliclazide, glipizide, glimepiride or tolbutamide**). **Bisoprolol could increase the risk of severely low blood glucose levels when used with these medicines.**

Annex III

Timetable for the implementation of this position

Timetable for the implementation of this position

Adoption of CMDh position:	June 2026 CMDh meeting
Transmission to National Competent Authorities of the translations of the annexes to the position:	10 August 2026
Implementation of the position by the Member States (submission of the variation by the Marketing Authorisation Holder):	9 October 2026